NAD+ BioavailabilityNCT07692633
A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
A study testing NAD+ in people with NAD+ Bioavailability and NAD+ Safety, run by Reus Research at 1 site in Canada.
Trial summary
The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo? Researchers will compare the NAD+… Read more about this study
- Who is it for?
- Ages 40 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- NAD+ Bioavailability, NAD+ Safety, NAD+ Efficacy
- What is being tested?
- NAD+
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteCanada
- Study dates
- Aug 2026to Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females between 40 and 65 years of age, inclusive, at screening
- Body Mass Index (BMI) between 18.5 and 29.9 kg/m2
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
Show all 16Show fewer
- Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Abstinence and agrees to use contraception if planning on becoming sexually active during the study
- Willingness to complete questionnaires and diaries associated with the study and to complete all visits
- Agrees to maintain current lifestyle habits (physical activity, medications, supplements, and sleep) as much as possible throughout the study
- Agrees to follow the specified low NAD-precursor diet during the run-in period and throughout the study
- Agrees to avoid caffeine (e.g., tea, coffee, energy drinks) for 12 hours (h) prior to post-screening in-clinic study visits
- Agrees to avoid alcohol consumption and vigorous physical activity for 24 h prior to post-screening in-clinic study visits
- Provided voluntary, written, informed consent to participate in the study
- Healthy as determined by medical history and laboratory results as assessed by the Qualified Investigator (QI)
Who cannot join
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product (test material's active or inactive ingredient) or placebo ingredients
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 1)
- Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
Show all 24Show fewer
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
- Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- Individuals with an autoimmune disease or are immune compromised as assessed by the QI
- Self-reported confirmation of a human immunodeficiency virus (HIV)-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
- Self-reported confirmation of blood/bleeding disorders as assessed by the QI
- Use of medical cannabinoid products
- Chronic use of cannabinoid products (>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
- Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
- Alcohol intake average of >2 standard drinks per day as assessed by the QI
- Alcohol or drug abuse within the last 12 months
- Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2)
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
- Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
- Individuals who are cognitively impaired and/or who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized, Triple-blind, Placebo Controlled Parallel Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo? Researchers will compare the NAD+ supplement to placebo to evaluate its absorption, safety, and efficacy. Participants will be asked to:
- Complete questionnaires
- Provide blood samples
- Consume either the NAD+ supplement or a placebo for 55 days
- Have their endothelial function evaluated
- Conditions
- NAD+ Bioavailability, NAD+ Safety, NAD+ Efficacy
- Being tested
- NAD+, Placebo
- Keywords
- NAD+, Nicotinamide adenine dinucleotide
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NAD+Dietary supplement
Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.
PlaceboDietary supplement
Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.
| Study group | Role | What they receive |
|---|---|---|
| NAD+ | Experimental | Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. Receives: Dietary Supplement: NAD+ |
| Placebo | Placebo comparator | Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo.
Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo.
Measured: Day 0 to 56
Secondary outcomes (7)
Change in NAD+ levels in whole blood from baseline to days 14 and 28 between the NAD+ supplement and placebo.
Change in NAD+ levels in whole blood from baseline to days 14 and 28 between the NAD+ supplement and placebo.
Measured: Baseline to Days 14 and 28
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in Cognitive function
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in cognitive function, as assessed by the Patient Reported Outcomes Measurement Information System (PROMIS) Cognitive Function- Short Form 8a. Raw scores range from 8 to 40, with higher scores indicating better perceived cognitive function.
Measured: Baseline to Days 28 and 56
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in appearance and aesthetics
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in appearance and aesthetics, as assessed by the Appearance and Aesthetics Likert Scale. The Appearance and Aesthetic Likert Scale is a five-point Likert scale that assesses participant level of satisfaction with their appearance. The scales ranges from 1-not satisfied at all to 5-very satisfied.
Measured: Baseline to days 28 and 56
Change from baseline to day 56 between the NAD+ supplement and placebo in energy and metabolism
Change from baseline to day 56 between the NAD+ supplement and placebo in energy and metabolism, as assessed by plasma adenosine triphosphate (ATP) production
Measured: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in cellular health and longevity
Change from baseline to day 56 between the NAD+ supplement and placebo in cellular health and longevity, as assessed by mitochondrial depolarization via 8-hydroxy-2'-deoxyguanosine (8OH-dG)
Measured: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in oxidative stress
Change from baseline to day 56 between the NAD+ supplement and placebo in oxidative stress, as assessed by reduced glutathione/glutathione disulfide (GSH/GSSG) ratio
Measured: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in cardiometabolic health
Change from baseline to day 56 between the NAD+ supplement and placebo in cardiometabolic health, as assessed by reactive hyperemia index (RHI) via EndoPAT machine
Measured: Day 0 to 56
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2026
- Study startAug 2026 (estimated)
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NAD+ BioavailabilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Reus Research
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07692633
- Sponsor's protocol ID
- 25RRCRR01
- Status last verified
- Aug 2026
- First submitted
- 3 Jul 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Triple-blind, Placebo Controlled Parallel Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults
- ClinicalTrials.gov ID
- NCT07692633
- Acronym / sponsor ID
- 25RRCRR01
- Conditions
- NAD+ Bioavailability, NAD+ Safety, NAD+ Efficacy
- Keywords
- NAD+, Nicotinamide adenine dinucleotide
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Reus ResearchIndustry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Study start
- Aug 2026 (estimated)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 9 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo? Researchers will compare the NAD+ supplement to placebo to evaluate its absorption, safety, and efficacy. Participants will be asked to:
- Complete questionnaires
- Provide blood samples
- Consume either the NAD+ supplement or a placebo for 55 days
- Have their endothelial function evaluated
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NAD+ | Experimental | Dietary Supplement: NAD+Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Males and females between 40 and 65 years of age, inclusive, at screening
- Body Mass Index (BMI) between 18.5 and 29.9 kg/m2
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Willingness to complete questionnaires and diaries associated with the study and to complete all visits
- Agrees to maintain current lifestyle habits (physical activity, medications, supplements, and sleep) as much as possible throughout the study
Key exclusion criteria (24 listed)
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product (test material's active or inactive ingredient) or placebo ingredients
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 1)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NAD+Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. | Dietary supplement | NAD+ |
| PlaceboParticipants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit. | Dietary supplement | Placebo |
Primary outcome
Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo.
Time frame: Day 0 to 56
Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo.
7 secondary outcomes
Change in NAD+ levels in whole blood from baseline to days 14 and 28 between the NAD+ supplement and placebo.
Time frame: Baseline to Days 14 and 28
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in Cognitive function
Time frame: Baseline to Days 28 and 56
Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in appearance and aesthetics
Time frame: Baseline to days 28 and 56
Change from baseline to day 56 between the NAD+ supplement and placebo in energy and metabolism
Time frame: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in cellular health and longevity
Time frame: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in oxidative stress
Time frame: Day 0 to 56
Change from baseline to day 56 between the NAD+ supplement and placebo in cardiometabolic health
Time frame: Day 0 to 56
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for NAD+ Bioavailability
RecruitingPhase 1
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
NAD+ Metabolism, Pharmacokinetics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NAD+ in people with NAD+ Bioavailability and NAD+ Safety, run by Reus Research at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Erin Lewis (+248 1-226-242-4551, elewis@kgkscience.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo. (time frame: Day 0 to 56). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.